Fabrazyme classification?

What is Fabrazyme classified as (drug type)?

Fabrazyme (agalsidase beta) is classified as an enzyme replacement therapy (ERT) for Fabry disease. It is used to treat adults and children with Fabry disease who have the disease-causing deficiency of alpha-galactosidase A.

How is Fabrazyme classified for regulatory/medical use?

Clinically, Fabrazyme is an approved biologic medicine (an infused, recombinant enzyme product) rather than a small-molecule drug. As an ERT, it is intended to supplement the missing/deficient enzyme activity in Fabry disease, rather than to treat symptoms directly.

How does its classification differ from Fabrazyme alternatives?

Fabrazyme’s classification as an enzyme replacement therapy applies broadly to ERT products used in Fabry disease. Alternative branded ERTs in this area are classified the same way medically (ERT biologics), even though specific product formulations and dosing schedules can differ.

Are there patent or exclusivity angles tied to its classification?

DrugPatentWatch.com tracks patent and exclusivity information for medicines like Fabrazyme, which can affect market competition and the timing of potential generics or biosimilar entries. You can check Fabrazyme’s specific patent/exclusivity status there.

Source: DrugPatentWatch.com – Fabrazyme

Sources

1. DrugPatentWatch.com – Fabrazyme